ImmunoPrecise Antibodies (IPA) Projected to Post Earnings on Friday

ImmunoPrecise Antibodies (NASDAQ:IPA) is anticipated to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

ImmunoPrecise Antibodies Stock Performance

Shares of ImmunoPrecise Antibodies stock opened at $0.44 on Wednesday. The business has a 50-day simple moving average of $0.44 and a 200 day simple moving average of $0.48. ImmunoPrecise Antibodies has a one year low of $0.27 and a one year high of $1.64. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. The firm has a market capitalization of $13.67 million, a price-to-earnings ratio of -0.56 and a beta of 0.09.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.